- Home
- DLO vs IBRX Comparison
DLO vs IBRX Comparison
Compare DLO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLO
- IBRX
- Stock Information
- Founded
- DLO 2013
- IBRX 2014
- Country
- DLO Uruguay
- IBRX United States
- Employees
- DLO N/A
- IBRX N/A
- Industry
- DLO Business Services
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DLO Consumer Discretionary
- IBRX Health Care
- Exchange
- DLO Nasdaq
- IBRX Nasdaq
- Market Cap
- DLO 2.6B
- IBRX 2.4B
- IPO Year
- DLO 2021
- IBRX N/A
- Fundamental
- Price
- DLO $8.33
- IBRX $3.14
- Analyst Decision
- DLO Hold
- IBRX Strong Buy
- Analyst Count
- DLO 11
- IBRX 5
- Target Price
- DLO $12.86
- IBRX $11.35
- AVG Volume (30 Days)
- DLO 1.1M
- IBRX 5.7M
- Earning Date
- DLO 05-13-2025
- IBRX 03-03-2025
- Dividend Yield
- DLO N/A
- IBRX N/A
- EPS Growth
- DLO N/A
- IBRX N/A
- EPS
- DLO 0.39
- IBRX N/A
- Revenue
- DLO $745,974,000.00
- IBRX $14,745,000.00
- Revenue This Year
- DLO $29.37
- IBRX $753.44
- Revenue Next Year
- DLO $25.69
- IBRX $174.29
- P/E Ratio
- DLO $21.36
- IBRX N/A
- Revenue Growth
- DLO 14.70
- IBRX 2270.58
- 52 Week Low
- DLO $6.58
- IBRX $2.28
- 52 Week High
- DLO $16.79
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- DLO 33.84
- IBRX 54.11
- Support Level
- DLO $9.17
- IBRX $2.69
- Resistance Level
- DLO $9.80
- IBRX $2.89
- Average True Range (ATR)
- DLO 0.41
- IBRX 0.21
- MACD
- DLO 0.06
- IBRX 0.05
- Stochastic Oscillator
- DLO 7.55
- IBRX 58.23
About DLO DLocal Limited
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables global enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.